In addition, the BC PDX tumors treated in vivo with tamoxifen or fulvestrant (Figure 1D) for 2 weeks showed increased HEY1 and HES1 expression (Figure 2B), supporting an increased role for the Notch signaling pathway after endocrine therapies. This evidence concerns the gene HES1 and breast cancer.